盘面上，业绩预升、芯片、房地产、培养钻石等板块涨幅居前，电机制造、旅游、消费电子、贵金属等板块跌幅居前。 半导体设备板块出现涨停潮，长川科技"20cm"两连板，张江高科、洪田股份盘中涨停，华海清科、微导纳米、矽电股份、上海新阳、盛美上海、京仪装 备、拓荆科技等均涨超10%。 销售旺季房地产利好政策不断 房地产股早间集体走强，板块指数盘初一度放量直线拉升涨逾3%。深振业Ａ开盘仅约2分钟就垂直涨停，股价创年内新高，云南城投、渝开发、上海临 港、张江高科等也纷纷直线涨停，并创阶段性新高。 | 分时 | 多日 1分 5分 15分 30分 60分 日 周 月 更多 | | | | | F9 盘前盘后 叠加 九转 画线 工具 ◎ 2 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 9.27 | 00006 深振业 A 11:30 价 9.27 涨跌 0.84(9.96%) 均价 9.12 成交量 50 成交金额 5万 | | | | | 2025/09/24 | 9.96% | | | | | | | | Win.日人气榜 第811名 | | | 8.85 ...

Core Viewpoint - Changchuan Technology forecasts a significant increase in net profit for Q3 2023, driven by strong demand in the semiconductor industry and increased sales revenue [1] Group 1: Company Performance - Changchuan Technology expects net profit for the first three quarters to be between 827 million to 877 million yuan, representing a year-on-year growth of 131.39% to 145.38% [1] - For Q3, Changchuan Technology anticipates a net profit of 400 million to 450 million yuan, reflecting a year-on-year increase of 180.67% to 215.75% [1] - Brother Technology projects a net profit of 100 million to 115 million yuan for the first three quarters, with a year-on-year growth of 207.32% to 253.42% [1] - Brother Technology expects Q3 net profit to be between 35.459 million to 50.459 million yuan, showing a year-on-year increase of 92.49% to 173.92% [1] Group 2: Factors Influencing Performance - The growth in Changchuan Technology's performance is attributed to the continuous growth in market demand within the semiconductor industry, leading to a substantial increase in product orders and sales revenue [1] - Brother Technology's performance improvement is linked to rising prices of certain vitamin products, enhanced capacity utilization of its phenol project, increased sales volume, and a decrease in costs, resulting in a higher overall gross margin [1] - Zhongtai Co. anticipates a net profit of 325 million to 355 million yuan for the first three quarters, with a year-on-year growth of 71.36% to 87.19%, driven by increased overseas revenue [2] Group 3: Production and Orders - Companies like Zhongtai Co. report that domestic and international orders have normalized, contributing to profit growth [2] - Companies such as Zhongtian Precision Decoration and Fangyuan Co. have indicated improvements in production capacity and profitability, with plans for increased utilization and market expansion [2][3] - Unigroup Guowei has noted an increase in orders for its special integrated circuit business since early July 2025, with its eSIM solutions being widely adopted across various sectors [3]

Group 1 - The core point of the article is that Brother Technology's subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received a drug registration certificate for Iopamidol injection, which is now approved for market sale in China [1][3] - The Iopamidol injection is classified as a Class 4 chemical drug and has been included in the National Medical Insurance Class A directory and the seventh batch of national drug centralized procurement [1][3] - The domestic market size for Iopamidol is projected to be approximately 450 million yuan in 2024, indicating a significant market opportunity for the company [1] Group 2 - On September 22, Brother Technology's stock closed at 7.17 yuan, down 1.92%, with a turnover rate of 13.39% and a trading volume of 939,200 shares, amounting to a transaction value of 675 million yuan [1] - The net outflow of main funds on September 22 was 40.2 million yuan, while retail investors saw a net inflow of 48.0 million yuan [1][3] - The approval of the drug registration certificate is expected to enhance the company's product line in iodine contrast agents and improve its market competitiveness [1]

Group 1 - The company conducted an online investor meeting on September 22, 2025, with nine investment institutions including Shanghai Haineng Investment and Jiangsu Gaotou Venture Capital [1] - The company has successfully entered the PEEK field by optimizing the process of phenol production, which is a core raw material for PEEK, previously supplied mainly by foreign companies [1] - The price of Vitamin B1 has increased compared to the same period last year, while other vitamin products have remained stable or slightly decreased [1] Group 2 - The company has expanded its market for iodine contrast agents, primarily selling to India, Turkey, and Russia, and has established a broad cooperation with Qidu Pharmaceutical to develop the domestic market [1] - The investor meeting did not involve any undisclosed significant information [1]

Group 1: Company Overview - The company is primarily introduced by the Secretary of the Board, Qian Liuhua, covering its development history, main products and application areas, production bases, downstream customers, and development strategy [2]. Group 2: Product Applications and Market Position - The process of phenol production for PEEK applications has higher purity and lower impurity requirements, making it more complex; the company has optimized its process over a long period and officially entered the PEEK field last year [2]. - Phenol is a core raw material for PEEK, traditionally supplied by foreign companies; in the first half of 2025, the company has completed sample submissions to major domestic PEEK manufacturers and is actively promoting its products [2]. Group 3: Financial Performance - The continuous improvement in Q3 performance is mainly due to the price increase of Vitamin B1, enhanced capacity utilization of the phenol project, increased sales volume, and a decrease in some product costs, leading to an overall increase in gross margin [3]. - The price fluctuations of vitamin products are influenced by supply-demand structure, cost changes, industry cycles, and competition; Vitamin B1 prices have increased compared to the same period last year, while other vitamin varieties remain stable or slightly decreased [3]. Group 4: Market Expansion - The company's iodine contrast agent is primarily sold in international markets such as India, Turkey, and Russia; after obtaining the Chinese registration for iodine contrast agent last year, the company has actively pursued domestic customer development, achieving extensive cooperation with Qidu Pharmaceutical [3]. Group 5: Disclosure Information - This investor relations activity does not involve any undisclosed significant information [3].

Group 1 - Global Printing announced that shareholder Hong Kong Yuanshi International Co., Ltd. plans to reduce its stake by up to 3.2004 million shares, accounting for 1% of the total share capital, due to personal funding needs [1] - Sunflower intends to acquire 100% equity of Xi Pu Materials and 40% equity of Zhejiang Beid Pharmaceutical through a combination of share issuance and cash payment, with stock resuming trading on September 22, 2025 [1][2] - Crown Zhong Ecology is planning a change in control, leading to a temporary suspension of its stock and convertible bonds due to significant uncertainties [2] Group 2 - China Oil Engineering's wholly-owned subsidiary signed a $513 million EPC contract for an LNG pipeline project in the UAE, covering approximately 180.5 kilometers of natural gas pipeline with a 36-month construction period [3] - Shanxi Fenjiu announced that shareholder Huachuang Xinrui (Hong Kong) Co., Ltd. plans to reduce its stake by up to 16.2006 million shares, representing no more than 1.33% of the total share capital [4] - Brother Technology's subsidiary received a drug registration certificate for Iopamidol injection, which is included in the national medical insurance catalog [5] Group 3 - Lin Yang Energy is expected to win a bid for a metering equipment project from the State Grid, with an estimated total bid amount of approximately 142 million yuan [6] - Huahai Chengke received approval from the China Securities Regulatory Commission for issuing shares and convertible bonds to purchase assets and raise no more than 800 million yuan in matching funds [8] - Jindi Co. signed a framework agreement to acquire controlling interest in Unico Precision, which specializes in manufacturing gears and automotive parts [10] Group 4 - Ruifeng High Materials announced that its major shareholder plans to reduce its stake by up to 2.4 million shares, accounting for 0.9584% of the total share capital [12] - Changliang Technology's director plans to reduce his stake by 1.05 million shares, representing 0.129% of the total share capital [14] - Zhongjing Food's director plans to reduce his stake by up to 150,000 shares, accounting for 0.10% of the total share capital [16] Group 5 - Haitai Technology announced that two shareholders plan to reduce their stakes by a total of up to 2.53% of the total share capital [18] - Zhenlei Technology's chairman is under detention but the company states that control has not changed and operations remain normal [20] - Huakang Co. plans to distribute a cash dividend of 0.2 yuan per share, totaling approximately 60.61 million yuan [19]

Core Viewpoint - The performance of the Zhongzheng 2000 Enhanced ETF (159552) shows a slight increase of 0.15% as of the midday close on September 22, with a trading volume of 28.4 million yuan [1] Group 1: ETF Performance - The Zhongzheng 2000 Enhanced ETF (159552) closed at 1.978 yuan, with a year-to-date return of 97.44% since its establishment on June 19, 2024 [1] - The ETF has experienced a decline of 1.47% over the past month [1] Group 2: Top Holdings Performance - Among the top holdings, Ice Glacier Network decreased by 1.72%, while New Asia Electronics increased by 2.39% [1] - Other notable movements include Huazheng New Materials down by 0.89%, Junya Technology up by 0.07%, and Shenchi Electromechanical up by 2.59% [1] - Brother Technology fell by 1.64%, Haitai Technology down by 2.10%, Changrong Co. down by 1.71%, and Focus Technology down by 0.79% [1] - Jingquan Hua saw an increase of 2.04% [1]

人民财讯9月21日电，兄弟科技（002562）9月21日公告，全资子公司浙江兄弟药业有限公司于近日收到 国家药品监督管理局核准签发的《药品注册证书》。药品名称为碘帕醇注射液，碘帕醇注射液主要用于 心血管造影、周围动脉造影及静脉造影、冠状动脉造影、脑血管造影、尿路造影、腰/胸及颈段脊髓造 影、关节造影等及CT增强检查，具有粘度低、安全性好等特点。 ...

Core Viewpoint - Brother Technology (002562) has received approval from the National Medical Products Administration for the iodine contrast agent injection, Iohexol, allowing for its official market launch in China, which enhances the company's competitiveness in the contrast agent sector [1] Group 1 - Brother Technology's wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has obtained the drug registration certificate for Iohexol injection [1] - Iohexol injection is primarily used for various types of angiography and CT enhancement examinations, characterized by low viscosity and good safety [1] - The approval for Iohexol injection marks a significant step for Brother Pharmaceutical in commercializing this product and expanding its iodine contrast agent product line [1]

Core Viewpoint - Brother Technology (002562.SZ) announced that its wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd., has received the drug registration certificate for Iohexol injection from the National Medical Products Administration, allowing for commercial sales in China [1] Group 1 - The Iohexol injection is primarily used for various types of imaging procedures, including cardiovascular, peripheral artery, venous, coronary, cerebral, urinary tract, spinal, and joint imaging, as well as CT enhancement [1] - The product is characterized by low viscosity and good safety, which are significant advantages in its application [1] - The approval for Iohexol injection marks a significant step for Brother Pharmaceutical in commercializing this product, enhancing its product line of iodine contrast agents and increasing its competitiveness in the contrast agent market [1]